Murakami Aya, Noto Keisuke, Ota Ryosuke, Hirata Atsushi
Department of Pharmacy, Kindai University Nara Hospital.
Yakugaku Zasshi. 2022;142(6):641-649. doi: 10.1248/yakushi.21-00175.
Bevacizumab (BV) is a recombinant and humanized monoclonal antibody that inhibits vascular endothelial growth factor. BV is used to treat various types of cancer. Proteinuria is a characteristic adverse event that occurs as a result of treatment with BV. However, the onset timing of proteinuria after BV administration remains unclear. In the present study, we examined the risk factors affecting the timing of proteinuria onset upon BV administration. Medical records of 135 patients (62 males and 73 females; mean age: 67.8±10.7 years) treated with BV were reviewed at the Kindai University Nara Hospital from April 2011 to December 2019. Proteinuria was identified in 44.4% (60/135) of the studied patients. The time to the first onset of proteinuria was significantly shorter in the administration of doses of BV (≥10) and history of diabetes mellitus. The median cumulative dose associated with the onset of proteinuria was 30.0 (16.1-58.8) mg/kg. When this cumulative dose was compared with 10 mg/kg, no significant difference was observed (p=0.319). The present study demonstrated that the administration of doses of BV (≥10) and history of diabetes mellitus are one of the main risk factors for early-onset proteinuria. These findings may be useful for the future treatment of early-onset proteinuria in patients treated with BV.
贝伐单抗（BV）是一种重组人源化单克隆抗体，可抑制血管内皮生长因子。BV用于治疗多种类型的癌症。蛋白尿是BV治疗导致的一种特征性不良事件。然而，BV给药后蛋白尿的发病时间仍不清楚。在本研究中，我们研究了影响BV给药后蛋白尿发病时间的危险因素。对2011年4月至2019年12月在近畿大学奈良医院接受BV治疗的135例患者（62例男性和73例女性；平均年龄：67.8±10.7岁）的病历进行了回顾。在44.4%（60/135）的研究患者中发现了蛋白尿。在给予BV剂量（≥10）和有糖尿病史的患者中，首次出现蛋白尿的时间明显较短。与蛋白尿发病相关的累积剂量中位数为30.0（16.1-58.8）mg/kg。将该累积剂量与10mg/kg进行比较时，未观察到显著差异（p=0.319）。本研究表明，给予BV剂量（≥10）和有糖尿病史是早发性蛋白尿的主要危险因素之一。这些发现可能对未来BV治疗患者的早发性蛋白尿治疗有用。
